taurine has been researched along with Reperfusion Injury in 73 studies
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As a non-toxic endogenous antioxidant, the semi-essential amino acid taurine is a potential attenuator of oxidative damage such as that produced by ischaemia-reperfusion injury." | 8.82 | The therapeutic role of taurine in ischaemia-reperfusion injury. ( Kelly, CJ; Kingston, R; Murray, P, 2004) |
| "Taurine is reported to reduce tissue damage induced by inflammation and to protect the brain against experimental stroke." | 7.78 | Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB. ( Gu, Y; Sun, M; Xu, C; Zhao, Y, 2012) |
| "This study shows that preconditioning with taurine or glycine is equally effective in preventing injury to fatty livers most likely via Kupffer cell-dependent mechanisms." | 7.77 | Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study. ( Bruns, H; Büchler, MW; Flechtenmacher, C; Galli, U; Gebhard, MM; Schemmer, P; Schulze-Bergkamen, H; Watanpour, I; Zorn, M, 2011) |
| "Our results suggest that taurine attenuates endoplasmic reticulum stress-induced apoptosis in the lungs of rats after limb ischemia reperfusion." | 7.76 | Taurine protects against lung damage following limb ischemia reperfusion in the rat by attenuating endoplasmic reticulum stress-induced apoptosis. ( Cao, G; Gao, J; Han, S; Lu, H; Men, X; Pu, J; Yu, H; Zhang, L, 2010) |
| "To investigate the effect of pretreatment with taurine on liver injury changes and the change of tumor necrosis factor alpha and NFkappaB expression following rats limbs ischemia/reperfusion." | 7.75 | [Effects of taurine on TNF-alpha and NF-kappaB expression of liver injury after limbs ischemia/reperfusion in rats]. ( Dong, SY; Kong, XY; Wang, YH; Zhang, LY; Zhang, N; Zhao, LJ, 2009) |
| "To evaluate the effect of taurine, a potent antioxidant, on testicular ischemia-reperfusion injury due to excess reactive oxygen species produced by neutrophils after testicular torsion-detorsion." | 7.74 | Beneficial effect of taurine on testicular ischemia-reperfusion injury in rats. ( Wei, SM; Yan, ZZ; Zhou, J, 2007) |
| "Preservation of fast twitch strength following ischaemia-reperfusion injury by administration of taurine before ischaemia has clinical potential." | 7.73 | Effects of systemic and regional taurine on skeletal muscle function following ischaemia-reperfusion injury. ( Kearns, S; Kelly, C; Kingston, R; Murray, P, 2005) |
| "The data show that taurine protects livers from ischemia-reoxygenation." | 7.70 | Taurine attenuates cold ischemia-reoxygenation injury in rat liver. ( Häussinger, D; Wettstein, M, 2000) |
| "These data show that pharmaceutical use of the endogenous amino acid taurine, unlike many-other agents, protects electrophysiological function in skeletal muscle against both early and late ischaemia-reperfusion injury." | 7.70 | Taurine protects against early and late skeletal muscle dysfunction secondary to ischaemia reperfusion injury. ( Bouchier-Hayes, D; Bowler, D; Kay, E; Kelly, CJ; McLaughlin, R, 2000) |
| " Ouabain and monensin mimicked reperfusion injury and their toxicity was also reduced by taurine." | 7.69 | Protective effect of taurine against reperfusion injury in cultured rat astrocytes. ( Azuma, J; Baba, A; Kishida, Y; Matsuda, T; Takuma, K, 1996) |
| "The protective effect of taurine on ischemia-reperfusion damages of rat perfused liver and its possible mechanism were investigated." | 7.68 | [Protective action of taurine on ischemia-reperfusion liver injury in rats and its mechanism]. ( Chen, YX, 1993) |
| "Taurine was administered 45 min prior to induction of ischemia." | 5.46 | Protective effects of taurine against renal ischemia/reperfusion injury in rats by inhibition of gelatinases, MMP-2 and MMP-9, and p38 mitogen-activated protein kinase signaling. ( Akdogan, G; Arslan, S; Camsari, T; Cavdar, Z; Celik, A; Ergur, UB; Guneli, E; Ozbal, S; Terzioglu, G; Ural, C; Yildiz, S, 2017) |
| "Taurine (TAU) is a sulfur-containing amino acid that is involved in a diverse array of biological and physiological functions, including bile salt conjugation, osmoregulation, membrane stabilization, calcium modulation, anti-oxidation, and immunomodulation." | 5.43 | Effect of taurine on intestinal recovery following intestinal ischemia-reperfusion injury in a rat. ( Aranovich, I; Ben Shahar, Y; Berkowitz, D; Bitterman, A; Bitterman, N; Chepurov, D; Coran, AG; Pollak, Y; Sukhotnik, I, 2016) |
| "Taurine is an organic acid, which has a very important function in the human body." | 5.37 | Effects of taurine on reperfusion injury. ( Akdemir, O; Arslan, Z; Hede, Y; Lineaweaver, WC; Songur, E; Zhang, F, 2011) |
| "Taurine is an endogenous antioxidant and a membrane-stabilizing, intracellular, free beta-amino acid." | 5.34 | The effect of taurine on renal ischemia/reperfusion injury. ( Demirogullari, B; Guz, G; Karasu, C; Lortlar, N; Nurlu, N; Omeroglu, S; Oz, E; Sert, S; Ulusu, NN, 2007) |
| "Ischemia-reperfusion injury is of major clinical relevance during liver transplantation." | 5.33 | Taurine protects against ischemia-reperfusion injury in rabbit livers. ( Jiang, H; Li, J; Meng, F; Qiao, H; Sun, X; Tong, L, 2006) |
| "NO may play an important role in lung injury induced by shock/reperfusion." | 5.32 | [Relationship between lung injury induced by hemorrhagic shock/reperfusion and nitric oxide and beneficial effect of taurine]. ( Chu, CJ; Deng, FM; He, F; Sun, ZP; Zhong, H, 2004) |
| "taurine (200 mg/kg) was intravenously injected 5 min before heart ischemia." | 5.32 | [Effects of taurine on rabbit cardiomyocyte apoptosis during ischemia/reperfusion injury]. ( Ji, ES; Li, AY; Li, Q; Ma, ZH; Zhao, SM, 2004) |
| "As a non-toxic endogenous antioxidant, the semi-essential amino acid taurine is a potential attenuator of oxidative damage such as that produced by ischaemia-reperfusion injury." | 4.82 | The therapeutic role of taurine in ischaemia-reperfusion injury. ( Kelly, CJ; Kingston, R; Murray, P, 2004) |
| " The effects of USC-Exo on ferroptosis and lncRNA taurine-upregulated gene 1 (TUG1) were detected in hypoxia/reoxygenation (H/R)-treated human proximal tubular epithelial cells (HK-2)." | 4.12 | Exosomal lncRNA TUG1 derived from human urine-derived stem cells attenuates renal ischemia/reperfusion injury by interacting with SRSF1 to regulate ASCL4-mediated ferroptosis. ( Bi, Q; Sun, Z; Wang, W; Wu, J, 2022) |
| "Emerging evidence has suggested that hydrogen sulfide (H2S) may alleviate the cellular damage associated with cerebral ischemia/reperfusion (I/R) injury." | 3.85 | The administration of hydrogen sulphide prior to ischemic reperfusion has neuroprotective effects in an acute stroke model. ( Choi, CG; Choi, Y; Ha, HK; Ham, SJ; Jeon, SB; Jung, SC; Kim, J; Kim, JK; Kim, KW; Kim, ST; Kwon, JI; Shim, WH; Sung, YS; Woo, CW; Woo, DC, 2017) |
| "Taurine is reported to reduce tissue damage induced by inflammation and to protect the brain against experimental stroke." | 3.78 | Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB. ( Gu, Y; Sun, M; Xu, C; Zhao, Y, 2012) |
| "This study shows that preconditioning with taurine or glycine is equally effective in preventing injury to fatty livers most likely via Kupffer cell-dependent mechanisms." | 3.77 | Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study. ( Bruns, H; Büchler, MW; Flechtenmacher, C; Galli, U; Gebhard, MM; Schemmer, P; Schulze-Bergkamen, H; Watanpour, I; Zorn, M, 2011) |
| "Our results suggest that taurine attenuates endoplasmic reticulum stress-induced apoptosis in the lungs of rats after limb ischemia reperfusion." | 3.76 | Taurine protects against lung damage following limb ischemia reperfusion in the rat by attenuating endoplasmic reticulum stress-induced apoptosis. ( Cao, G; Gao, J; Han, S; Lu, H; Men, X; Pu, J; Yu, H; Zhang, L, 2010) |
| "To investigate the effect of pretreatment with taurine on liver injury changes and the change of tumor necrosis factor alpha and NFkappaB expression following rats limbs ischemia/reperfusion." | 3.75 | [Effects of taurine on TNF-alpha and NF-kappaB expression of liver injury after limbs ischemia/reperfusion in rats]. ( Dong, SY; Kong, XY; Wang, YH; Zhang, LY; Zhang, N; Zhao, LJ, 2009) |
| "To evaluate the effect of taurine, a potent antioxidant, on testicular ischemia-reperfusion injury due to excess reactive oxygen species produced by neutrophils after testicular torsion-detorsion." | 3.74 | Beneficial effect of taurine on testicular ischemia-reperfusion injury in rats. ( Wei, SM; Yan, ZZ; Zhou, J, 2007) |
| "This study demonstrates that donor preconditioning with taurine protects kidney grafts from injury (apoptosis, necrosis), improves graft function, and increases the regenerative potential most likely via mechanisms including antioxidation." | 3.74 | Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation. ( Büchler, MW; Dei-Anane, G; Gross, ML; Guan, X; Kern, M; Liang, R; Ludwig, J; Nickkholgh, A; Schemmer, P; Schmidt, J; Zeier, M, 2008) |
| "Preservation of fast twitch strength following ischaemia-reperfusion injury by administration of taurine before ischaemia has clinical potential." | 3.73 | Effects of systemic and regional taurine on skeletal muscle function following ischaemia-reperfusion injury. ( Kearns, S; Kelly, C; Kingston, R; Murray, P, 2005) |
| "An experimental comparative study on isolated guinea pig-lungs has been undertaken to determine the probable beneficial effects of adding taurine to pulmonary reperfusion solutions in lung ischemia-reperfusion." | 3.71 | The role of taurine added to pulmonary reperfusion solutions in isolated guinea pig lungs. ( Altunkaya, A; Halit, V; Oz, E; Sivrikoz, MC; Take, G, 2002) |
| "We examined the effect of ellagic acid (EA), one of the polyphenols that are abundantly contained in whisky as a nonalcoholic component, on gastric lesions induced by ammonia plus ischemia or ischemia/reperfusion in rats, in relation to the antioxidative system." | 3.71 | Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion. ( Iino, T; Ogawa, Y; Takata, K; Takeeda, M; Takeuchi, K; Tashima, K; Umeda, M, 2002) |
| "The data show that taurine protects livers from ischemia-reoxygenation." | 3.70 | Taurine attenuates cold ischemia-reoxygenation injury in rat liver. ( Häussinger, D; Wettstein, M, 2000) |
| "These data show that pharmaceutical use of the endogenous amino acid taurine, unlike many-other agents, protects electrophysiological function in skeletal muscle against both early and late ischaemia-reperfusion injury." | 3.70 | Taurine protects against early and late skeletal muscle dysfunction secondary to ischaemia reperfusion injury. ( Bouchier-Hayes, D; Bowler, D; Kay, E; Kelly, CJ; McLaughlin, R, 2000) |
| " Ouabain and monensin mimicked reperfusion injury and their toxicity was also reduced by taurine." | 3.69 | Protective effect of taurine against reperfusion injury in cultured rat astrocytes. ( Azuma, J; Baba, A; Kishida, Y; Matsuda, T; Takuma, K, 1996) |
| "The protective effect of taurine on ischemia-reperfusion damages of rat perfused liver and its possible mechanism were investigated." | 3.68 | [Protective action of taurine on ischemia-reperfusion liver injury in rats and its mechanism]. ( Chen, YX, 1993) |
| "Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
| "Icaritin (ICT) has been previously demonstrated to display protective effects against cerebral ischemic reperfusion (I/R) by inhibiting oxidative stress, but the mechanism remains unclear." | 1.91 | UHPLC-ESI-QE-Orbitrap-MS based metabolomics reveals the antioxidant mechanism of icaritin on mice with cerebral ischemic reperfusion. ( Feng, Z; Liu, Z; Sun, C; Sun, L; Tang, Y; Yao, J; Zhang, G; Zhao, Y, 2023) |
| "Taurine was administered 45 min prior to induction of ischemia." | 1.46 | Protective effects of taurine against renal ischemia/reperfusion injury in rats by inhibition of gelatinases, MMP-2 and MMP-9, and p38 mitogen-activated protein kinase signaling. ( Akdogan, G; Arslan, S; Camsari, T; Cavdar, Z; Celik, A; Ergur, UB; Guneli, E; Ozbal, S; Terzioglu, G; Ural, C; Yildiz, S, 2017) |
| "Taurine (TAU) is a sulfur-containing amino acid that is involved in a diverse array of biological and physiological functions, including bile salt conjugation, osmoregulation, membrane stabilization, calcium modulation, anti-oxidation, and immunomodulation." | 1.43 | Effect of taurine on intestinal recovery following intestinal ischemia-reperfusion injury in a rat. ( Aranovich, I; Ben Shahar, Y; Berkowitz, D; Bitterman, A; Bitterman, N; Chepurov, D; Coran, AG; Pollak, Y; Sukhotnik, I, 2016) |
| "Those that developed cerebral ischemia after MCAO were randomized to receive propylene glycol salt water and ligustrazine respectively." | 1.40 | Effect of ligustrazine on levels of amino acid neurotransmitters in rat striatum after cerebral ischemia-reperfusion injury. ( Bie, XD; Ge, LJ; Han, J; Wan, HT; Yang, JH; Zhang, YY, 2014) |
| "Taurine is an organic acid, which has a very important function in the human body." | 1.37 | Effects of taurine on reperfusion injury. ( Akdemir, O; Arslan, Z; Hede, Y; Lineaweaver, WC; Songur, E; Zhang, F, 2011) |
| "Taurine has been shown to protect organs from ischemia reperfusion or endotoxin by its anti-oxidant and anti-inflammatory activities." | 1.36 | Protective effects of taurine against endotoxin-induced acute liver injury after hepatic ischemia reperfusion. ( Chen, X; Jiang, H; Mao, Y; Qiao, H; Sun, X; Tong, L; Zhang, F; Zhao, H, 2010) |
| "Ischemia/reperfusion injury is mediated by various mechanisms." | 1.35 | Fundamental efforts toward the development of a therapeutic cocktail with a manifold ameliorative effect on hepatic ischemia/reperfusion injury. ( Backhaus, J; Büchler, MW; Flechtenmacher, C; Gebhard, MM; Kincius, M; Liang, R; Schemmer, P; Schindler, G; Zorn, M, 2009) |
| "Taurine was intravenously injected to Wistar rats 30 min before II/R; physiological saline and sham operation served as controls." | 1.35 | Taurine attenuates multiple organ injury induced by intestinal ischemia reperfusion in rats. ( Dong, X; Jiang, H; Qiao, G; Qiao, H; Sun, X; Tong, L; Zhang, F, 2008) |
| "Taurine is an endogenous antioxidant and a membrane-stabilizing, intracellular, free beta-amino acid." | 1.34 | The effect of taurine on renal ischemia/reperfusion injury. ( Demirogullari, B; Guz, G; Karasu, C; Lortlar, N; Nurlu, N; Omeroglu, S; Oz, E; Sert, S; Ulusu, NN, 2007) |
| "Ischemia-reperfusion injury is of major clinical relevance during liver transplantation." | 1.33 | Taurine protects against ischemia-reperfusion injury in rabbit livers. ( Jiang, H; Li, J; Meng, F; Qiao, H; Sun, X; Tong, L, 2006) |
| "In taurine-treated animals, at 2h reperfusion, the mean arterial blood pressure and heart rate were increased, by 6% and 10%." | 1.33 | Taurine inhibits ischemia/reperfusion-induced compartment syndrome in rabbits. ( Li, Y; Pang, YZ; Tang, CS; Wang, JX; Zhang, J; Zhang, LK; Zhao, J, 2005) |
| " Compared with the model group, the concentration of Glu in the middle and large dosage groups of TGF, during the 120 min of ischemia, reduced by 38." | 1.32 | [Effects of tianma gouteng fang on transmitter amino acids in the hippocampus extracellular liquids in freely moving rats subjected to brain ischemia]. ( Du, GY; Sun, XF; Wang, DQ; Wang, W; Ye, ZG; Zhang, CY; Zhao, DZ, 2004) |
| "NO may play an important role in lung injury induced by shock/reperfusion." | 1.32 | [Relationship between lung injury induced by hemorrhagic shock/reperfusion and nitric oxide and beneficial effect of taurine]. ( Chu, CJ; Deng, FM; He, F; Sun, ZP; Zhong, H, 2004) |
| "taurine (200 mg/kg) was intravenously injected 5 min before heart ischemia." | 1.32 | [Effects of taurine on rabbit cardiomyocyte apoptosis during ischemia/reperfusion injury]. ( Ji, ES; Li, AY; Li, Q; Ma, ZH; Zhao, SM, 2004) |
| "Taurine (4% solution) was administrated orally for 48 h prior to the experiment." | 1.30 | Differential effects of lower limb revascularisation on organ injury and the role of the amino acid taurine. ( Abdih, H; Barry, MC; Hayes, DB; Kelly, CJ; Redmond, HP; Sheehan, SJ; Stapleton, P; Watson, RW, 1997) |
| "Like taurine, there were no significant changes in the intracellular concentration of ATP after ischaemia in the two groups of patients (from 3." | 1.30 | Warm blood cardioplegia reduces the fall in the intracellular concentration of taurine in the ischaemic/reperfused heart of patients undergoing aortic valve surgery. ( Angelini, GD; Ascione, R; Bryan, AJ; Gomes, WJ; Suleiman, MS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (20.55) | 18.2507 |
| 2000's | 34 (46.58) | 29.6817 |
| 2010's | 21 (28.77) | 24.3611 |
| 2020's | 3 (4.11) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Z | 1 |
| Wu, J | 1 |
| Bi, Q | 1 |
| Wang, W | 2 |
| Tang, Y | 1 |
| Sun, L | 1 |
| Zhao, Y | 2 |
| Yao, J | 1 |
| Feng, Z | 1 |
| Liu, Z | 1 |
| Zhang, G | 1 |
| Sun, C | 1 |
| Qiu, S | 1 |
| Li, X | 1 |
| Zhang, J | 2 |
| Shi, P | 1 |
| Cao, Y | 1 |
| Zhuang, Y | 1 |
| Tong, L | 4 |
| Kulthinee, S | 2 |
| Wyss, JM | 2 |
| Roysommuti, S | 2 |
| Cavdar, Z | 1 |
| Ural, C | 1 |
| Celik, A | 1 |
| Arslan, S | 1 |
| Terzioglu, G | 1 |
| Ozbal, S | 1 |
| Yildiz, S | 1 |
| Ergur, UB | 1 |
| Guneli, E | 1 |
| Camsari, T | 1 |
| Akdogan, G | 1 |
| Woo, CW | 1 |
| Kwon, JI | 1 |
| Kim, KW | 1 |
| Kim, JK | 1 |
| Jeon, SB | 1 |
| Jung, SC | 1 |
| Choi, CG | 1 |
| Kim, ST | 1 |
| Kim, J | 1 |
| Ham, SJ | 1 |
| Shim, WH | 1 |
| Sung, YS | 1 |
| Ha, HK | 1 |
| Choi, Y | 1 |
| Woo, DC | 1 |
| Chen, L | 1 |
| Chao, Y | 1 |
| Cheng, P | 1 |
| Li, N | 1 |
| Zheng, H | 1 |
| Yang, Y | 1 |
| Guler, L | 1 |
| Tavlasoglu, M | 1 |
| Yucel, O | 1 |
| Guler, A | 1 |
| Sahin, MA | 1 |
| Kurkluoglu, M | 1 |
| Sirin, Y | 1 |
| Eken, A | 1 |
| Gamsizkan, M | 1 |
| Dakak, M | 1 |
| Gurkok, S | 1 |
| Genc, O | 1 |
| Rukan, TA | 1 |
| Mksimovich, NE | 1 |
| Zimatkin, SM | 1 |
| Han, J | 1 |
| Wan, HT | 1 |
| Yang, JH | 1 |
| Zhang, YY | 1 |
| Ge, LJ | 1 |
| Bie, XD | 1 |
| Aydos, TR | 1 |
| Başar, MM | 1 |
| Kul, O | 1 |
| Atmaca, HT | 1 |
| Uzunalıoğlu, T | 1 |
| Kisa, Ü | 1 |
| Efe, OE | 1 |
| Sukhotnik, I | 1 |
| Aranovich, I | 1 |
| Ben Shahar, Y | 1 |
| Bitterman, N | 1 |
| Pollak, Y | 1 |
| Berkowitz, D | 1 |
| Chepurov, D | 1 |
| Coran, AG | 1 |
| Bitterman, A | 1 |
| Zhang, F | 3 |
| Qiao, H | 3 |
| Dong, X | 1 |
| Qiao, G | 1 |
| Jiang, H | 3 |
| Sun, X | 3 |
| Mao, Y | 1 |
| Zhao, H | 1 |
| Chen, X | 1 |
| Schindler, G | 1 |
| Kincius, M | 2 |
| Liang, R | 3 |
| Backhaus, J | 1 |
| Zorn, M | 2 |
| Flechtenmacher, C | 3 |
| Gebhard, MM | 3 |
| Büchler, MW | 4 |
| Schemmer, P | 5 |
| Ricci, L | 2 |
| Valoti, M | 3 |
| Sgaragli, G | 3 |
| Frosini, M | 2 |
| Men, X | 1 |
| Han, S | 1 |
| Gao, J | 1 |
| Cao, G | 1 |
| Zhang, L | 1 |
| Yu, H | 1 |
| Lu, H | 1 |
| Pu, J | 1 |
| Doddakula, KK | 1 |
| Neary, PM | 1 |
| Wang, JH | 1 |
| Sookhai, S | 1 |
| O'Donnell, A | 1 |
| Aherne, T | 1 |
| Bouchier-Hayes, DJ | 1 |
| Redmond, HP | 2 |
| Jirakulsomchok, D | 1 |
| Mozaffari, MS | 1 |
| Abdelsayed, R | 1 |
| Patel, C | 1 |
| Wimborne, H | 1 |
| Liu, JY | 1 |
| Schaffer, SW | 1 |
| Chesney, RW | 1 |
| Han, X | 1 |
| Patters, AB | 1 |
| He, F | 1 |
| Sun, ZP | 1 |
| Deng, FM | 1 |
| Zhong, H | 1 |
| Chu, CJ | 1 |
| Bruns, H | 1 |
| Watanpour, I | 1 |
| Galli, U | 1 |
| Schulze-Bergkamen, H | 1 |
| Men, SL | 1 |
| Xiong, JX | 1 |
| Li, HJ | 1 |
| Zhang, N | 1 |
| Zhang, LY | 2 |
| Wang, YH | 1 |
| Dong, SY | 2 |
| Kong, XY | 1 |
| Zhao, LJ | 1 |
| Li, AY | 1 |
| Ji, ES | 1 |
| Zhao, SM | 1 |
| Ma, ZH | 1 |
| Li, Q | 1 |
| Men, XL | 1 |
| Sun, SX | 1 |
| Zhang, YB | 1 |
| Akdemir, O | 1 |
| Hede, Y | 1 |
| Lineaweaver, WC | 1 |
| Arslan, Z | 1 |
| Songur, E | 1 |
| Sun, M | 1 |
| Gu, Y | 1 |
| Xu, C | 1 |
| Kirov, A | 1 |
| Duarte, M | 1 |
| Guay, J | 1 |
| Karolak, M | 1 |
| Yan, C | 1 |
| Oxburgh, L | 1 |
| Prudovsky, I | 1 |
| Abbasoğlu, L | 1 |
| Kalaz, EB | 1 |
| Soluk-Tekkeşin, M | 1 |
| Olgaç, V | 1 |
| Doğru-Abbasoğlu, S | 1 |
| Uysal, M | 1 |
| Nanobashvili, J | 1 |
| Neumayer, C | 1 |
| Fügl, A | 1 |
| Punz, A | 1 |
| Blumer, R | 1 |
| Prager, M | 1 |
| Mittlböck, M | 1 |
| Gruber, H | 1 |
| Polterauer, P | 1 |
| Roth, E | 1 |
| Malinski, T | 1 |
| Huk, I | 1 |
| Michalk, DV | 1 |
| Hoffmann, B | 1 |
| Minor, T | 2 |
| Melis, GC | 1 |
| ter Wengel, N | 1 |
| Boelens, PG | 1 |
| van Leeuwen, PA | 1 |
| Kingston, R | 2 |
| Kelly, CJ | 3 |
| Murray, P | 2 |
| Büyükuysal, RL | 1 |
| Kavianipour, M | 1 |
| Wikström, G | 2 |
| Ronquist, G | 2 |
| Waldenström, A | 2 |
| Zhang, CY | 1 |
| Du, GY | 1 |
| Ye, ZG | 1 |
| Wang, DQ | 1 |
| Sun, XF | 1 |
| Zhao, DZ | 1 |
| Kearns, S | 1 |
| Kelly, C | 1 |
| Wang, JX | 1 |
| Li, Y | 1 |
| Zhang, LK | 1 |
| Zhao, J | 1 |
| Pang, YZ | 1 |
| Tang, CS | 1 |
| Li, J | 1 |
| Meng, F | 1 |
| Guz, G | 1 |
| Oz, E | 3 |
| Lortlar, N | 1 |
| Ulusu, NN | 1 |
| Nurlu, N | 1 |
| Demirogullari, B | 1 |
| Omeroglu, S | 1 |
| Sert, S | 1 |
| Karasu, C | 1 |
| Nickkholgh, A | 2 |
| Hoffmann, K | 1 |
| Ryschich, E | 1 |
| Gutt, CN | 1 |
| Schmidt, J | 2 |
| Guan, X | 1 |
| Dei-Anane, G | 1 |
| Gross, ML | 1 |
| Kern, M | 1 |
| Ludwig, J | 1 |
| Zeier, M | 1 |
| Wei, SM | 2 |
| Yan, ZZ | 2 |
| Zhou, J | 2 |
| Namazi, H | 1 |
| Chen, YX | 1 |
| Matsumoto, K | 1 |
| Lo, EH | 1 |
| Pierce, AR | 1 |
| Halpern, EF | 1 |
| Newcomb, R | 1 |
| Yamaguchi, T | 1 |
| Klauke, H | 1 |
| Wingenfeld, P | 1 |
| Michalk, D | 1 |
| Isselhard, W | 1 |
| Matsuda, T | 1 |
| Takuma, K | 1 |
| Kishida, Y | 1 |
| Azuma, J | 1 |
| Baba, A | 1 |
| Delbarre, B | 1 |
| Delbarre, G | 1 |
| Calinon, F | 1 |
| Barry, MC | 1 |
| Abdih, H | 1 |
| Watson, RW | 1 |
| Stapleton, P | 1 |
| Sheehan, SJ | 1 |
| Hayes, DB | 1 |
| Wettstein, M | 2 |
| Häussinger, D | 2 |
| Yoshida, WB | 1 |
| Alasio, T | 1 |
| Mazziotta, R | 1 |
| Qin, F | 1 |
| Kashani, M | 1 |
| Lee, S | 1 |
| Dardik, H | 1 |
| Becker, R | 1 |
| Kimelberg, HK | 1 |
| Mongin, AA | 1 |
| Ascione, R | 1 |
| Gomes, WJ | 1 |
| Angelini, GD | 1 |
| Bryan, AJ | 1 |
| Suleiman, MS | 1 |
| Erbaş, D | 1 |
| Gelir, E | 1 |
| Aricioğlu, A | 1 |
| Phillis, JW | 4 |
| Song, D | 2 |
| Guyot, LL | 3 |
| O'Regan, MH | 4 |
| Diaz, FG | 2 |
| Cañas, PE | 1 |
| Ren, J | 2 |
| McLaughlin, R | 1 |
| Bowler, D | 1 |
| Kay, E | 1 |
| Bouchier-Hayes, D | 1 |
| Miyamoto, TA | 1 |
| Miyamoto, KJ | 1 |
| Wheeler, MD | 1 |
| Ikejema, K | 1 |
| Enomoto, N | 1 |
| Stacklewitz, RF | 1 |
| Seabra, V | 1 |
| Zhong, Z | 1 |
| Yin, M | 1 |
| Rose, ML | 1 |
| Rusyn, I | 1 |
| Bradford, B | 1 |
| Thurman, RG | 1 |
| Zemgulis, V | 1 |
| Bjerner, T | 1 |
| Henze, A | 1 |
| Thelin, S | 1 |
| Pessina, F | 1 |
| Matteucci, G | 1 |
| Esposito, L | 1 |
| Gorelli, B | 1 |
| Iino, T | 1 |
| Tashima, K | 1 |
| Umeda, M | 1 |
| Ogawa, Y | 1 |
| Takeeda, M | 1 |
| Takata, K | 1 |
| Takeuchi, K | 1 |
| Sivrikoz, MC | 1 |
| Halit, V | 1 |
| Altunkaya, A | 1 |
| Take, G | 1 |
| Zhou, M | 1 |
| Ma, T | 1 |
| Tseng, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
| Glycine | 109.7 | 133.9 | 115.3 |
| Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |
|---|---|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
| Glycine | 104.1 | 111.8 |
| Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
| Glycine | 105.2 | 105.2 | 115.5 |
| Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
| Glycine | 82.0 | 75.6 | 77.7 |
| Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
6 reviews available for taurine and Reperfusion Injury
| Article | Year |
|---|---|
Taurine and the renal system.
Topics: Animals; Apoptosis; Cell Cycle; Humans; Ions; Kidney; Kidney Diseases; Kidney Glomerulus; Osmolar Co | 2010 |
Glutamine: recent developments in research on the clinical significance of glutamine.
Topics: Animals; Clinical Trials as Topic; Dietary Supplements; Glutamine; Glutathione; Humans; Intestinal M | 2004 |
The therapeutic role of taurine in ischaemia-reperfusion injury.
Topics: Animals; Antioxidants; Ascorbic Acid; Clinical Trials as Topic; Disease Models, Animal; Free Radical | 2004 |
Swelling-activated release of excitatory amino acids in the brain: relevance for pathophysiology.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfo | 1998 |
The role of xanthine oxidase and the effects of antioxidants in ischemia reperfusion cell injury.
Topics: Antioxidants; Enzyme Inhibitors; Free Radicals; Humans; Ischemia; Neutrophils; Reactive Oxygen Speci | 1999 |
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
1 trial available for taurine and Reperfusion Injury
| Article | Year |
|---|---|
The antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine.
Topics: Aged; Antioxidants; Cardiopulmonary Bypass; Constriction; Coronary Artery Bypass; Endotoxins; Female | 2010 |
66 other studies available for taurine and Reperfusion Injury
| Article | Year |
|---|---|
Exosomal lncRNA TUG1 derived from human urine-derived stem cells attenuates renal ischemia/reperfusion injury by interacting with SRSF1 to regulate ASCL4-mediated ferroptosis.
Topics: Acute Kidney Injury; Animals; Ferroptosis; Humans; Hypoxia; Ischemia; Kidney; Mice; Mice, Inbred C57 | 2022 |
UHPLC-ESI-QE-Orbitrap-MS based metabolomics reveals the antioxidant mechanism of icaritin on mice with cerebral ischemic reperfusion.
Topics: Animals; Antioxidants; Arachidonic Acid; Chromatography, High Pressure Liquid; gamma-Aminobutyric Ac | 2023 |
Neutrophil membrane-coated taurine nanoparticles protect against hepatic ischemia-reperfusion injury.
Topics: Glutathione; Humans; Interleukin-6; Liver; Liver Diseases; Neutrophils; Oxidative Stress; Reperfusio | 2023 |
Taurine Supplementation Inhibits Cardiac and Systemic Renin-Angiotensin System Overactivity After Cardiac Ischemia/Reperfusion in Adult Female Rats Perinatally Depleted of Taurine Followed by High Sugar Intake.
Topics: Animals; Dietary Sugars; Dietary Supplements; Female; Myocardial Ischemia; Pregnancy; Rats; Rats, Sp | 2019 |
Protective effects of taurine against renal ischemia/reperfusion injury in rats by inhibition of gelatinases, MMP-2 and MMP-9, and p38 mitogen-activated protein kinase signaling.
Topics: Animals; Blotting, Western; Gelatinases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase | 2017 |
The administration of hydrogen sulphide prior to ischemic reperfusion has neuroprotective effects in an acute stroke model.
Topics: Animals; Apoptosis; Aspartic Acid; Brain Ischemia; Disease Models, Animal; Glutamic Acid; Humans; Hy | 2017 |
UPLC-QTOF/MS-Based Metabolomics Reveals the Protective Mechanism of Hydrogen on Mice with Ischemic Stroke.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Energy Metabolism; Glutathione; Hydrogen; Infa | 2019 |
Taurine attenuates lung ischemia-reperfusion injury after lung transplantation in rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Hypertonic Solutions; Lung; Lung Transplantation; Mal | 2014 |
[Morphofunctional state of vessel endothelium at the early stage of cerebral ischemia-reperfusion and the effect of taurin administration].
Topics: Animals; Blood Coagulation; Brain; Endothelial Cells; Endothelium, Vascular; Male; Platelet Aggregat | 2013 |
Effect of ligustrazine on levels of amino acid neurotransmitters in rat striatum after cerebral ischemia-reperfusion injury.
Topics: Amino Acids; Animals; Aspartic Acid; Brain; Brain Ischemia; Corpus Striatum; gamma-Aminobutyric Acid | 2014 |
Effects of ozone therapy and taurine on ischemia/reperfusion-induced testicular injury in a rat testicular torsion model.
Topics: Animals; Antioxidants; Disease Models, Animal; In Situ Nick-End Labeling; Male; Oxidants, Photochemi | 2014 |
Effect of taurine on intestinal recovery following intestinal ischemia-reperfusion injury in a rat.
Topics: Animals; Blotting, Western; Disease Models, Animal; Intestines; Male; Rats; Rats, Sprague-Dawley; Re | 2016 |
Taurine attenuates multiple organ injury induced by intestinal ischemia reperfusion in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Disease Models, Animal; Injections, Intr | 2008 |
Protective effects of taurine against endotoxin-induced acute liver injury after hepatic ischemia reperfusion.
Topics: Animals; Caspase 3; Endotoxins; Injections, Intravenous; L-Lactate Dehydrogenase; Liver; Male; Malon | 2010 |
Fundamental efforts toward the development of a therapeutic cocktail with a manifold ameliorative effect on hepatic ischemia/reperfusion injury.
Topics: Alanine; Animals; Arginine; Chemotaxis, Leukocyte; Clinical Enzyme Tests; Drug Therapy, Combination; | 2009 |
Protection by taurine of rat brain cortical slices against oxygen glucose deprivation- and reoxygenation-induced damage.
Topics: Animals; Biomimetics; Brain; Chloride Channels; Edema; Glucose; Glutamic Acid; In Vitro Techniques; | 2009 |
Taurine protects against lung damage following limb ischemia reperfusion in the rat by attenuating endoplasmic reticulum stress-induced apoptosis.
Topics: Animals; Apoptosis; Disease Models, Animal; Endoplasmic Reticulum; Ischemia; Lung; Male; Oxidative S | 2010 |
High sugar intake exacerbates cardiac reperfusion injury in perinatal taurine depleted adult rats.
Topics: Animals; Baroreflex; Blood Pressure; Body Weight; Dietary Carbohydrates; Female; Heart Rate; Humans; | 2010 |
Differential effects of taurine treatment and taurine deficiency on the outcome of renal ischemia reperfusion injury.
Topics: Animals; Apoptosis; Aquaporin 2; Cell Proliferation; Kidney; Kidney Diseases; Kidney Function Tests; | 2010 |
[Relationship between lung injury induced by hemorrhagic shock/reperfusion and nitric oxide and beneficial effect of taurine].
Topics: Animals; Lung; Lung Injury; Nitric Oxide; Nitric Oxide Synthase; Rabbits; Reperfusion Injury; Shock, | 2004 |
Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study.
Topics: Animals; Cell Communication; Clinical Enzyme Tests; Fatty Liver; Female; Glycine; Kupffer Cells; Mic | 2011 |
[Effects of taurine on the changes of PLA2 during acute lung injury following limbs ischemia/reperfusion of rats].
Topics: Acute Lung Injury; Animals; Extremities; Group II Phospholipases A2; Male; Rats; Rats, Wistar; Reper | 2007 |
[Effects of taurine on TNF-alpha and NF-kappaB expression of liver injury after limbs ischemia/reperfusion in rats].
Topics: Animals; Extremities; Ischemia; Liver; Male; NF-kappa B; Protective Agents; Random Allocation; Rats; | 2009 |
[Effects of taurine on rabbit cardiomyocyte apoptosis during ischemia/reperfusion injury].
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Male; Myocardial Ischemia; Myocytes, Cardiac; Rab | 2004 |
[The protective effect of taurine on lung injury following limbs ischemia/reperfusion of rats].
Topics: Animals; Hindlimb; Lung; Lung Injury; Male; Malondialdehyde; Rats; Rats, Wistar; Reactive Oxygen Spe | 2004 |
Effects of taurine on reperfusion injury.
Topics: Animals; Antioxidants; Biopsy, Needle; Disease Models, Animal; Follow-Up Studies; Graft Rejection; G | 2011 |
Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB.
Topics: Animals; Anti-Inflammatory Agents; Brain; Cell Death; Disease Models, Animal; Gene Expression Regula | 2012 |
Taurine-like GABA aminotransferase inhibitors prevent rabbit brain slices against oxygen-glucose deprivation-induced damage.
Topics: 4-Aminobutyrate Transaminase; Animals; Brain; Brain Ischemia; gamma-Aminobutyric Acid; Glucose; Male | 2012 |
Transgenic expression of nonclassically secreted FGF suppresses kidney repair.
Topics: Animals; Base Sequence; Cell Enlargement; DNA Primers; Endothelial Cells; Fibroblast Growth Factor 1 | 2012 |
Beneficial effects of taurine and carnosine in experimental ischemia/reperfusion injury in testis.
Topics: Animals; Carnosine; Male; Rats; Rats, Wistar; Reperfusion Injury; Spermatic Cord Torsion; Taurine; T | 2012 |
Ischemia/reperfusion injury of skeletal muscle: plasma taurine as a measure of tissue damage.
Topics: Animals; Biomarkers; Cell Membrane; Creatine Kinase; L-Lactate Dehydrogenase; Male; Malondialdehyde; | 2003 |
Taurine reduces renal ischemia/reperfusion injury in the rat.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Ischemia; Isoenzymes; Kidney; L-Lactate Dehydrogenase; | 2003 |
Ischemia and reoxygenation induced amino acid release release and tissue damage in the slices of rat corpus striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Brain; Calcium; Citrulline; Corpus Striatum; Female; gamma-Amin | 2004 |
Validity of elevated interstitial levels of taurine as a predictor of myocardial ischemic injury.
Topics: Animals; Area Under Curve; Ischemia; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfus | 2004 |
[Effects of tianma gouteng fang on transmitter amino acids in the hippocampus extracellular liquids in freely moving rats subjected to brain ischemia].
Topics: Animals; Arginine; Brain Ischemia; Drug Combinations; Drugs, Chinese Herbal; Excitatory Amino Acids; | 2004 |
Effects of systemic and regional taurine on skeletal muscle function following ischaemia-reperfusion injury.
Topics: Animals; Dose-Response Relationship, Drug; Hindlimb; Male; Muscle Contraction; Muscle, Skeletal; Rat | 2005 |
Taurine inhibits ischemia/reperfusion-induced compartment syndrome in rabbits.
Topics: Animals; Compartment Syndromes; L-Lactate Dehydrogenase; Malondialdehyde; Muscle, Skeletal; Oxidativ | 2005 |
Taurine protects against ischemia-reperfusion injury in rabbit livers.
Topics: Animals; Disease Models, Animal; Injections, Intravenous; Kinetics; Lipid Peroxidation; Liver; Liver | 2006 |
The effect of taurine on renal ischemia/reperfusion injury.
Topics: Animals; Antioxidants; Biomarkers; Kidney; Kidney Diseases; Male; Random Allocation; Rats; Rats, Wis | 2007 |
Taurine protects from liver injury after warm ischemia in rats: the role of kupffer cells.
Topics: Animals; Cell Communication; Endothelial Cells; Female; Intercellular Adhesion Molecule-1; Kupffer C | 2007 |
Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation.
Topics: Animals; Apoptosis; Biopsy; Caspase 3; Dose-Response Relationship, Drug; Female; Graft Rejection; HS | 2008 |
Beneficial effect of taurine on testicular ischemia-reperfusion injury in rats.
Topics: Animals; Antioxidants; Biopsy; Germ Cells; Male; Malondialdehyde; Organ Size; Peroxidase; Rats; Rats | 2007 |
Novel molecular mechanism to account for action of taurine against testicular ischemia-reperfusion injury.
Topics: Down-Regulation; Endothelial Cells; Humans; Intercellular Adhesion Molecule-1; Lymphocyte Function-A | 2008 |
Taurine reduces testicular ischemia/reperfusion-induced neutrophil recruitment to testis probably by downregulation of pro-inflammatory cytokines and E-selectin.
Topics: Cytokines; Down-Regulation; E-Selectin; Humans; Interleukin-1beta; Male; Neutrophil Infiltration; Re | 2008 |
[Protective action of taurine on ischemia-reperfusion liver injury in rats and its mechanism].
Topics: Animals; Calcium; Ischemia; L-Lactate Dehydrogenase; Lipid Peroxides; Liver; Male; Malondialdehyde; | 1993 |
Secondary elevation of extracellular neurotransmitter amino acids in the reperfusion phase following focal cerebral ischemia.
Topics: Amino Acids; Analysis of Variance; Animals; Aspartic Acid; Basal Ganglia; Cerebral Cortex; Cerebrosp | 1996 |
Taurine reduces experimental liver injury after cold ischemic preservation and a period of rewarming prior to reperfusion.
Topics: Adenosine; Alanine Transaminase; Allopurinol; Animals; Biomarkers; Cold Temperature; Glutamate Dehyd | 1996 |
Protective effect of taurine against reperfusion injury in cultured rat astrocytes.
Topics: Animals; Animals, Newborn; Astrocytes; beta-Alanine; Calcium; Cell Survival; Cells, Cultured; Cerebr | 1996 |
Taurine in gerbil retina: changes during ischemia reperfusion/insult (I.R.I.) and aging.
Topics: Aging; Animals; Chromatography, High Pressure Liquid; Electrochemistry; Female; Gerbillinae; Ischemi | 1996 |
Differential effects of lower limb revascularisation on organ injury and the role of the amino acid taurine.
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Hindlimb; Kidney; Liver; Lung; Male; | 1997 |
Cytoprotection by the osmolytes betaine and taurine in ischemia-reoxygenation injury in the perfused rat liver.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Aminotransferases; Betaine; Cytoprotecti | 1997 |
Effect of alpha-tocopherol, taurine and selenium on the attenuation of ischemia/reperfusion injury of splanchnic organs.
Topics: Animals; Cecum; Disease Models, Animal; Duodenum; Ileum; Jejunum; Male; Random Allocation; Rats; Rat | 1998 |
Warm blood cardioplegia reduces the fall in the intracellular concentration of taurine in the ischaemic/reperfused heart of patients undergoing aortic valve surgery.
Topics: Adenosine Triphosphate; Aged; Aortic Valve; Aortic Valve Stenosis; Female; Heart Arrest, Induced; Hu | 1998 |
Taurine and calcium interaction in protection of myocardium exposed to ischemic reperfusion injury.
Topics: Animals; Calcium; Drug Combinations; Drug Interactions; Guinea Pigs; Heart Rate; Male; Malondialdehy | 1999 |
Lactate reduces amino acid release and fuels recovery of function in the ischemic brain.
Topics: Amino Acids; Animals; Brain Ischemia; Cerebral Cortex; Electroencephalography; Injections; Lactic Ac | 1999 |
Topical glucose and accumulation of excitotoxic and other amino acids in ischemic cerebral cortex.
Topics: Animals; Aspartic Acid; Blood Pressure; Brain Ischemia; Carbon Dioxide; Cerebral Cortex; Ethanolamin | 2000 |
Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex: studies with DL-threo-beta-benzyloxyaspartate.
Topics: Amino Acid Transport System X-AG; Animals; Aspartic Acid; ATP-Binding Cassette Transporters; Brain I | 2000 |
Taurine attenuates cold ischemia-reoxygenation injury in rat liver.
Topics: Animals; Betaine; Cryopreservation; Inositol; Ischemia; Liver; Liver Circulation; Male; Rats; Rats, | 2000 |
The effect of intravenous insulin on accumulation of excitotoxic and other amino acids in the ischemic rat cerebral cortex.
Topics: Animals; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Energy Metabolism; gamma-Aminobutyric Acid | 2000 |
Taurine protects against early and late skeletal muscle dysfunction secondary to ischaemia reperfusion injury.
Topics: Animals; Electrophysiology; Muscle Contraction; Muscle, Skeletal; Random Allocation; Rats; Rats, Spr | 2000 |
pH-stat strategies protect 60-minute central nervous system ischemia at 29.5 degrees C.
Topics: Animals; Central Nervous System; Humans; Hydrogen-Ion Concentration; Hypothermia, Induced; Rabbits; | 2000 |
Energy-related metabolites during and after induced myocardial infarction with special emphasis on the reperfusion injury after extracorporeal circulation.
Topics: Adenosine; Animals; Chromatography, High Pressure Liquid; Dialysis Solutions; Disease Models, Animal | 2001 |
Protection of intrinsic nerves of guinea-pig detrusor strips against anoxia/glucopenia and reperfusion injury by taurine.
Topics: Aminoethylphosphonic Acid; Animals; Atropine; Electric Stimulation; Evoked Potentials; Glucose; Guin | 2000 |
Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion.
Topics: Ammonia; Animals; Antioxidants; Dose-Response Relationship, Drug; Ellagic Acid; Gastric Mucosa; Isch | 2002 |
The role of taurine added to pulmonary reperfusion solutions in isolated guinea pig lungs.
Topics: Animals; Glutathione; Guinea Pigs; Ischemia; Lung; Male; Malondialdehyde; Protective Agents; Reperfu | 2002 |
Effects of taurine and ketamine on bovine retinal membrane lipid peroxidation.
Topics: Animals; Ascorbic Acid; Cadmium; Cadmium Chloride; Calcium; Cattle; Dextromethorphan; Female; Ischem | 1991 |